Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. Early-stage detection and diagnosis of HCC is of vital importance for medical treatment. 1 Currently, the diagnosis of HCC mainly depends on imaging findings. However, the sensitivity of contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), which are recommended for imaging lesions, is 76% and 61%, respectively. 2 Besides CT and MRI, 18 F-fluorodeoxyglucose ( 18 F-FDG) and 11 C-acetate positron emission tomography (PET) imaging have demonstrated their capability to detect and stage HCCs. The 18 F-FDG PET was introduced for detecting extrahepatic metastases and providing valuable prognostic information in liver transplantation and surgical resection. However, 18 F-FDG PET has limited value in diagnosing HCC owing to its low sensitivity. 3 The 18 F-FDG is far from being a universal tracer because tumor kinetics may vary and increased glycolysis may not be the preferred kinetic pathway in some tumors. Primary HCC exhibits broad 18 F-FDG uptake, thus reducing its sensitivity for tumor detection. The false-negative rate of 18 F-FDG PET/CT in HCC is as high as 40% to 50%. 2 Just as aerobic glycolysis can be a distinguishing attribute of cancer cells, most solid tumors are characterized by a lipogenic phenotype. Hence, fatty acid metabolism-in particular, their biosynthesis-has gained significant attention in the past decade as a biomarker and therapeutic target in multiple cancers. 4-6 11 C-acetate PET, with its higher sensitivity, is an important complement of 18 F-FDG. Combining 18 F-FDG with 11 C-acetate PET/CT has proven useful to clinicians managing patients with HCC. 7 Although the mechanism of 11 C-acetate uptake remains unclear, recent studies have shown that most prostate tumors overexpress fatty acid synthase (FASN), which uses acetate as its substrate for synthesizing short-chain fatty acids, and this could be the reason for the increased 11 C-acetate uptake in tumors. 8,9 11 C-acetate has shown promise in diagnosing and staging HCC. However, given the short half-life of carbon-11 (20.4 minutes), the use of 11 C-acetate to image tumors and monitor fatty acid synthesis would be limited to institutions with in-house cyclotrons. A potential acetate analog for effectively monitoring fatty acid synthesis could be 18 F-fluoroacetate ( 18 F-FAC). However, its drawbacks are its substantial bone uptake and characteristic of radiotracer defluorination that restrict its use. 10 18 F-fluoropropionic acid ( 18 F-FPA)-another important mimic of 11 C-acetate-has been proposed as a possible alternative for prostate and breast cancer imaging. 11, 12 It has a much higher uptake than acetate does for prostate cancer imaging. Unlike 18 F-FAC, 18 F-FPA shows low bone uptake and no evidence of defluorination.
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Our hypothesis was that 18 F-FPA would mimic 11 C-acetate and hence accumulate in HCCs, thereby allowing tumor delineation on PET. The PET imaging with 18 F-FPA combined with 18 F-FDG can be an alternative for detecting HCC. Therefore, the aim of this study was to evaluate the preclinical value of 18 F-FPA and 18 F-FDG PET for imaging HCCs.
Materials and Methods

General
All reagents, unless otherwise specified, were of analytical grade and commercially available. Sep-Pak Light QMA, Sep-Pak Plus C 18 , Oasis HLB, and SCX cartridges were obtained from Waters Corporation (Milford, Massachusetts). Sep-Pak Light QMA cartridges were preconditioned with 5 mL aqueous NaHCO 3 (8.4%) and 10 mL ethanol and water before use. Sep-Pak Plus C 18 and Oasis HLB cartridges were preconditioned with 10 mL ethanol and water before use. All high-performance liquid chromatography solvents were filtered before use. Radioactivity was measured using a gamma-counter (SN-6105, Shanghai Nuclear Rihuan Photoelectric Instrument, LLC, China).
Cell Culture and Animal Models
All experiments were performed under a protocol approved by the Sun Yat-sen University Institutional Animal Care and Use Committee. SK-Hep1 and Hep3B cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HepG2 cell line was obtained from the Laboratory Animal Centre of Sun Yat-sen University (Guangzhou, China).
The cells were cultivated in Dulbecco's modified Eagle's medium with a physiologic glucose concentration (1.0 g/L) containing 10% fetal calf serum at 37 C in a humidified atmosphere of 5% CO 2 and 95% air. The medium was routinely renewed 3 times a week. Exponentially growing cells were used for the experiments. BALB/c nude mice were obtained from the Laboratory Animal Centre of Sun Yat-sen University. The mice were kept in sterile surroundings with a standardized light/dark cycle and access to food and water ad libitum. The mice were 6 to 8 weeks old when used for the experiments. Subcutaneous tumors were produced in the BALB/c nude mice (16-20 g ) via subcutaneous injection of 5 Â 10 6 tumor cells in a 100-mL volume comprising 50 mL of the cell culture medium and 50 mL of Matrigel (BD Biosciences, New Jersey) on the forelimb of the mice. The 18 F-FPA and 18 F-FDG PET/CT were performed when the tumors were 5 to 8 mm in diameter.
Radiosynthesis
No-carrier-added 18 F-fluoride ion was obtained through the nuclear reaction 18 O(p, n) 18 F by irradiating more than 95% 18 O-enriched water targeted with 10-MeV protons using a Cyclone 10/5 cyclotron (IBA Technologies, Belgium).
The 18 F-FDG was synthesized automatically with a conventional module used in our clinical work and had a radiochemical purity of more than 95%. Automated radiosynthesis of 18 F-FPA was based on previously described methodology, 13 and the final radiochemical yield was around 45% (2%; n ¼ 20) with a radiochemical purity of more than 95%.
Cell Uptake Experiment
The Hep3B, HepG2, and SK-Hep1 HCC cells (*1 Â 10 7 ) were seeded on 24-well plates overnight and incubated for 24 hours in a humidified 5% CO 2 environment, at which time greater than 90% confluence was reached. Approximately 0.74 MBq 18 F-FPA or 18 F-FDG was then added to the wells and incubated at 37 C for 60 minutes. At the end of incubation, the cells were washed 2 times with phosphate-buffered saline (PBS) to remove free tracers and then lysed in 1% NaOH (500 mL for 20 minutes) and transferred to test tubes. Cellular tracer uptake was counted using the gamma-counter. The amount of radioactivity in the cells was normalized by the dose administered per well.
In Vitro Competitive Inhibition Study
The Hep3B, HepG2, and SK-Hep1 HCC cells were seeded on 24-well plates and incubated for 24 hours. After a 30-minute incubation period with orlistat or 5-tetradecyloxy-2-furoic acid (TOFA; run in a concentration series from 0 to 400 mM), 18 F-FPA were added at doses of approximately 0.74 MBq/well and the cells were incubated for 20 minutes. The cells were then washed 2 times with PBS, lysed in 1% NaOH (500 mL for 20 minutes), transferred to test tubes, and counted for 18 F activity in the gamma-counter. The amount of radioactivity in the cells was normalized by the dose administered per well. This experiment was repeated in triplicate, averaged on different days.
PET/CT Studies and Image Analysis
The PET/CT images were acquired using an Albira smallanimal PET/CT scanner (Bruker, Germany) after a bolus injection into the tumor-bearing mice. There were 3 group mice bearing different cell lines. Each group has 3 to 5 mice. The mice were anesthetized using 2% pentobarbital sodium (40 mg/ kg) and positioned prone on the scanning table. The mice were kept fasting for at least 4 hours and then 18 F-FPA was administered via the tail vein at a dose of 3.70 to 4.44 MBq in 0.2 mL of saline. On the following day, the mice were injected with 18 F-FDG in the same condition. Image data were acquired for 20 minutes after 60 minutes of the injection. Static PET scans were acquired and the CT scan was used for attenuation correction and localization of the lesion site. The Albira PET system and PMOD version 3.7 software (PMOD Technologies, Switzerland) were used for imaging construction and for drawing the regions of interest over the tumors and organs. Tumor radioactivity was normalized to that of the whole body to obtain the normalized uptake value to permit comparison of the data obtained.
Histopathology
The excised tumors were fixed in 4% paraformaldehyde and embedded in paraffin. Five-micron sections of each tissue were stained with hematoxylin and eosin, and the tumors were examined.
Immunofluorescence and Western Blotting
Immunofluorescence. The sections were fixed in 4% formaldehyde (10 minutes) and then incubated in 1% bovine serum albumin/10% normal goat serum/0.3 M glycine in 0.1% PBS-Tween for 1 hour to permeabilize the cells and block nonspecific protein-protein interactions. The cells were then incubated with glucose transporter-1 (GLUT1) and FASN antibodies (AB652/AB22759, 1:250/1:100, Abcam, UK) overnight at 4 C. The secondary antibody (red) was CY3 goat anti-rabbit (GB21303, Servicebio, China) immunoglobulin G used at a 1/300 dilution for 50 minutes. Fluorescein isothiocyanate (GB22303, Servicebio) was used at a 1/200 dilution for 50 minutes. 4 0 ,6-Diamidino-2-phenylindole (G1012, Servicebio) was used to stain the cell nuclei (blue) at a concentration of 1.43 mM.
Western blot analysis. The GLUT1, FASN, and matrix metalloproteinase-2 (MMP2) expression levels were measured using Western blot analysis. Samples were lysed with a lysis buffer containing a protease inhibitor cocktail (G2006, Servicebio), and the protein concentrations were determined using a protein assay kit (G2006, Servicebio). Sodium dodecyl sulfatepolyacrylamide gel electrophoresis was performed with 20 mg of protein in each sample using 4% to 15% Mini Protean TGX precast gels (Servicebio). The following primary antibodies were used: anti-GLUT1 (AB652, 1:1000, Abcam), anti-FASN (AB22759, 1:1000, Abcam), and anti-MMP2 (GB11130, 1:1000, Servicebio). The bands were detected using a Western blotting detection system (Epson, Japan) and band intensity was calculated via densitometry using AlphaEaseFC (Alpha Innotech, USA).
Statistical analysis. Quantitative data were expressed as means (standard deviation). Statistical analysis was performed using PASW Statistics for Windows, version 18.0 (SPSS Inc, Chicago, Illinois). An independent-sample t test was used for comparing the differences between the uptake of 18 F-FPA and 18 F-FDG. Analysis of variance was used for comparing between the HCC cell lines. The correlation between the results of Western blotting and radiotracer uptake was analyzed using linear regression analysis. P values <.05 were considered statistically significant.
Results
In Vitro Studies
The HCC cell lines showed significantly varied 18 F-FDG and 18 F-FPA uptakes ( Figure 1A and) . After incubation for 60 minutes, 18 F-FPA uptake in the Hep3B, HepG2, and SK-Hep1 cells reached 0.0024% (0.0003%), 0.0035% (0.0001%), and 0.0039% (0.0007%) radioactivity per microgram of protein, respectively (F ¼ 6.909, P ¼ .028). In contrast, 18 F-FDG uptake at the same point in the Hep3B, HepG2, and SKHep1 cells reached 0.0082% (0.0016%), 0.0067% (0.0022%), and 0.0059% (0.0016%) radioactivity per microgram of protein, respectively (F ¼ 1.394, P ¼ .330).
In SK-Hep1, HepG2, and Hep3B cells, the uptake of 18 F-FPA was inhibited 41.0% (3.0%), 41.6% (2.0%), and 34.7% (8.2%), respectively, by orilistat at 400 mM concentration ( Figure 1C) . The TOFA revealed a 26.0% (6.0%), 22.0% (2.8%), and 14.3% (2.1%) maximum decrease in 18 F-FPA uptake in SK-Hep1, HepG2, and Hep3B, respectively.
Comparison of
18 F-FPA and 18 
F-FDG for Tumor Detection
The PET/CT images were acquired 60 minutes after the injection (Figure 2 ). High tumor uptake was detected by PET/CT for 18 F-FPA or 18 F-FDG in HCCs, which showed a similar tendency to that seen in the in vitro study. In static 18 F-FPA scans, the tumors were clearly visible with high contrast to the contralateral background within the HepG2 and SK-Hep1 tumor animal models, whereas tumor-associated radioactivity with 18 F-FDG was not visible above the background in static scans. For HepG2 and SK-Hep1 tumors, the tumor-to-liver normalized uptakes were 1.40 (0.02) and 1.63 (0.26), respectively, at 60 minutes for 18 F-FPA, whereas they were 1.21 (0.08) and 1.09 (0.21) for 18 F-FDG (t ¼ 2.826, P ¼ .048; t ¼ 4.055, P ¼ .047). In contrast, for Hep3B tumors, the tumor-to-liver normalized uptake was 2.03 (0.25) at 60 minutes for 18 F-FDG, whereas it was 0.93 (0.15) for 18 F-FPA (t ¼ 6.472, P ¼ .006). Consistent with the tendency seen in other in vitro studies, tumor radioactivity was comparable to that of human HCC tumors. The 2 radiotracer uptake patterns seemed to complement each other in HCC tumors. For 18 F-FPA, the SK-Hep1 tumors showed 1.2-fold higher tumor-to-liver ratios than did the HepG2 tumors and 1.8-fold higher ratios than did the Hep3B tumor. Conversely, the tumor-to-liver ratios of 18 F-FDG in Hep3B tumors were higher than those in HepG2 (1.7-fold) and SK-Hep1 (1.9-fold) tumors.
Histopathological Finding of Tumors
A large number of heterotype cells can be seen in tumor tissues, confirming the success of tumor model making ( Figure 2C ).
Immunofluorescence Staining
Previous studies indicated that not all HCC tumor samples showed elevated FASN expression.
14 Notably, we found that the SK-Hep1 and HepG2 tumors showed more intense staining of FASN than did the Hep3B tumors, as shown in Figure 3 . In contrast, GLUT1 staining was weaker in the SK-Hep1 tumors than in the Hep3B tumors. The results were further confirmed by Western blotting ( Figure 4A ).
Western Blot and Linear Regression Analysis
Western blot analysis was performed to evaluate the expression of GLUT1, FASN, and MMP2 in SK-Hep1, HepG2, and Hep3B tumors ( Figure 4A ). Consistent with the results of immunofluorescence staining, the expression of FASN was greater in SK-Hep1 and HepG2 tumors than in Hep3B tumors. Hep3B tumors showed more GLUT1 expression than did the other tumors. A correlation was found between 18 F-FPA uptake and FASN expression (r ¼ 0.89, P ¼ .014) and MMP2 expression (r ¼ 0.77, P ¼ .002), as shown in Figure 4B and C.
Discussion
The combined 11 C-acetate and 18 F-FDG PET/CT protocol has been used to evaluate patients with HCC or suspicious liver masses. The results suggest that it has a mutual complementary advantage. 15 Despite the success of 11 C-acetate for diagnosing HCC tumors, the short half-life of 11 C limits its use as a routine PET agent. In contrast, 18 F-labeled tracers are advantageous because of their relatively longer half-life (2 hours) which does not necessitate an onsite cyclotron. One point to note is that 18 F-FPA had much higher uptake than 14 C-acetate in CWR22rv1 tumors, and the uptake ratio of tumor to some organs was more favorable for 18 F-FPA than for 14 C-acetate.
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This study investigated the potential of combining 18 F-FDG and 18 F-FPA PET as a diagnostic approach for HCCs. The interesting observation is that these 2 tracers are probably ). * P < .05, ** P < .01, *** P < .001. C, Histopathological examination using hematoxylin and eosin staining (H&E staining) in HCC tumor samples. Original magnification: Â100. NS indicates not statistically significant.
complementary to each other in detecting HCCs. Their combination would increase the sensitivity of PET/CT. When HCCs show a lower ID%/g for 18 F-FDG, the uptake of 18 F-FPA appears to be quite high. The 18 F-FPA shows promise for detecting tumors, which highly express FASN when 18 F-FDG PET/CT fails to detect HCCs, and provides more information about metastatic potentials which would be helpful for customizing tumor treatment in clinical practice.
The 18 F-FDG PET has been particularly effective in characterizing malignancies that have a glycolytic phenotype. However, various tumors, including primary HCCs, renal cell carcinomas, and certain types of lymphoma, are not easily visualized by 18 F-FDG PET. This is mainly because these tumors are generally not highly glycolytic and thus do not readily accumulate FDG. Although the experimental quantity was small, it is interesting to find that 18 F-FDG uptake in the HCC cell lines were so different and that the uptake eventually reflected the differences in the expression of GLUT1 that plays a vital role in 18 F-FDG uptake. Fatty acid synthesis occupies a central role in regulating multiple dynamic processes in tumor cells. Cancer cells often require fatty acids to maintain proliferation and viability. The ubiquitous requirement for fatty acid synthesis in cancer cells provides an opportunity to harness this trait using modern PET/ CT technology.
11 C-acetate has high sensitivity and specificity as a radiotracer complementary to 18 F-FDG in PET imaging of HCCs and evaluation of other liver masses. A high PET signal in tumors is often associated with increased expression of FASN and increased de novo lipogenesis in tumor tissues. 16 The 18 F-FPA, as a mimic of 11 C-acetate, has the potential to detect HCCs, and its connection to tumor pathobiology is discussed in our work. Generally, sodium, potassium, and calcium salts of propionic acid are extensively used as food additives. Metabolic studies have indicated that propionate can be used as a precursor for synthesizing fatty acids, glycogen, amino acids, and so on depending on the species. 17 Propionic acid metabolism begins with its conversion to propionyl-CoA catalyzed by mitochondrial propionyl-CoA-synthetases, as the first common step in the metabolism of fatty acids. 18, 19 Some studies have reported that propionate replaces acetate as a favored energy substrate in the heart and tumor cells, 20 and the net utilization of acetate by rat hepatocytes could be impaired by propionate. 21 Our study showed that 18 F-FPA is partly involved in de novo lipogenesis and may be another small fatty acid PET imaging agent for HCC. The uptake of 18 F-FPA was inhibited to varying degrees in the presence of inhibitors of fatty acid synthesis. These data demonstrated that orlistat and TOFA are more effective in HCC cell lines with high 18 F-FPA uptake. Orlistat, an antiobesity drug having very low oral bioavailability, has been approved by the US Food and Drug Administration. The activity of orlistat has been attributed to its FASN-blocking potential. It shows promising inhibitory effect on cell proliferation as well as tumor growth in prostate and breast cancer cells. 22 The finding that orlistat could reduce the uptake of 18 F-FPA by up to 42.7% in HCC cells indicated the important role of FASN in 18 F-FPA uptake. In accordance with the results of immunofluorescence and proteomic analyses, the expression of FASN was in the same order which may help explain the mechanism of 18 F-FPA uptake. In addition to FASN, other enzymes in the fatty acid synthesis pathway are commonly overexpressed in cancer. For example, the protein expression of acetyl-CoAcarboxylase (ACC), the rate-limiting enzyme upstream of FASN, has been shown to be upregulated in numerous tumor types. 23 The TOFA, a lipophilic fatty acid mimic that targets the carboxyltransferase activity of ACC, inhibited fatty acid synthesis in hepatocytes, rat liver homogenates, and male rat liver by reducing endogenous fatty acids that form part of the phospholipid composition of cell membranes. 24 In terms of 18 F-FPA, the treatment of HCC cell lines with TOFA blocked the uptake of this radiotracer even though its inhibition was less effective than that of orlistat. Given that 18 F-FPA incorporation into tumor cells directly correlates with the extent of fatty acid synthesis, the efficacy of treatment molecules that regulate the activity of fatty acid synthesis could easily be monitored using 18 F-FPA PET. The present data suggested that 18 F-FPA uptake is associated with increased expression of FASN and increased de novo lipogenesis in tumor tissues. Recent findings suggest that FASN might play a more or less pronounced role depending of the etiology associated with HCC development, at least in the early phases of hepatocarcinogenesis. 19, 25 Early upregulation of FASN in precursor lesions might represent an obligatory metabolic acquisition in response to the microenvironment of preinvasive lesions (ie, poor oxygenation and high acidity, and/or the lack of nutrients), which continue to occur in the invasive and/or metastatic stages. The FASN can work as a previously unrecognized metabolic intermediate of oncogenesis linking energy, anabolism, and malignant transformation. 26 Thus, we inferred that the FASN-related uptake of 18 F-FPA may provide more biological information regarding the development and progression of HCCs. The invasion and metastasis of liver cancer is a complex process in which the dissolution of the extracellular matrix plays an important role. The MMP2 is capable of degrading the majority of components of the extracellular matrix and is regarded to closely correlate with tumor invasion and metastasis. 27 In our study, MMP2 overexpression correlated well with 18 F-FPA uptake, and we hypothesized that 18 F-FPA can provide more information about the metastatic potential of HCC cell lines.
Some limitations of this study should be considered before drawing any conclusions. In vitro experiments, the uptake of 18 F-FDG is much higher than that of 18 F-FPA in HCC cell lines, suggesting that there are some differences in uptake capacity between tumor cells and tumor tissues. The differences in the microenvironment and other possible related factors should be taken into account. Additional studies are ongoing in more animals, and clinical studies are needed to confirm the relationship between the 2 tracers.
Conclusions
The patterns of 18 
